

# Srilatha Edupuganti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/749700/publications.pdf>

Version: 2024-02-01

44  
papers

4,529  
citations

361045

20  
h-index

288905

40  
g-index

47  
all docs

47  
docs citations

47  
times ranked

11252  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A cross-sectional analysis of subjects enrolled in the COVID-19 Prevention in Emory Healthcare Personnel (COPE) study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 381-386. | 1.0 | 10        |
| 2  | Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.   | 1.4 | 6         |
| 3  | Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-8.                        | 1.0 | 7         |
| 4  | EVITA Dengue: a cluster-randomized controlled trial to Evaluate the efficacy of Wolbachia-Infected <i>Aedes aegypti</i> mosquitoes in reducing the incidence of Arboviral infection in Brazil. <i>Trials</i> , 2022, 23, 185.  | 0.7 | 5         |
| 5  | Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1210-1220.  | 4.6 | 15        |
| 6  | Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.  | 0.8 | 19        |
| 7  | Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021, 64, 103203.   | 2.7 | 14        |
| 8  | Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021, 29, 516-521.e3.   | 5.1 | 199       |
| 9  | Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 671-679.  | 0.9 | 16        |
| 10 | A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 680-687.                                      | 0.9 | 25        |
| 11 | Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab315.   | 0.4 | 12        |
| 12 | Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. <i>Cell Reports Medicine</i> , 2021, 2, 100354.  | 3.3 | 316       |
| 13 | Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. <i>Microbiology Spectrum</i> , 2021, 9, e0045821.  | 1.2 | 3         |
| 14 | Application of SARS-CoV-2 Serology to Address Public Health Priorities. <i>Frontiers in Public Health</i> , 2021, 9, 744535.   | 1.3 | 4         |
| 15 | Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , the, 2020, 7, e688-e698.   | 2.1 | 58        |
| 16 | Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure. <i>Vaccines</i> , 2020, 8, 348.  | 2.1 | 4         |
| 17 | Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. <i>Science</i> , 2020, 369, 1210-1220.   | 6.0 | 947       |
| 18 | COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. <i>Journal of Clinical Microbiology</i> , 2020, 59, .   | 1.8 | 193       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). <i>Pediatrics</i> , 2020, 146, .  | 1.0  | 113       |
| 20 | Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GPÂ® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. <i>Vaccines</i> , 2020, 8, 741.  | 2.1  | 11        |
| 21 | The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , 2020, 5, .  | 5.6  | 772       |
| 22 | Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine. <i>Vaccines</i> , 2020, 8, 126.  | 2.1  | 1         |
| 23 | Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .  | 2.3  | 25        |
| 24 | Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 19071-19076.  | 3.3  | 30        |
| 25 | Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy352.  | 0.4  | 26        |
| 26 | 1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisition in Uninfected Individuals. <i>Open Forum Infectious Diseases</i> , 2019, 6, S457-S458. | 0.4  | 0         |
| 27 | Innate, T-, and B-Cell Responses in Acute Human Zika Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1-10.   | 2.9  | 162       |
| 28 | 2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S748-S748.   | 0.4  | 0         |
| 29 | Tularemia vaccine: Safety, reactogenicity, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain "A" A phase 2 randomized clinical trial. <i>Vaccine</i> , 2017, 35, 4730-4737.  | 1.7  | 30        |
| 30 | Origin and differentiation of human memory CD8 T cells after vaccination. <i>Nature</i> , 2017, 552, 362-367.  | 13.7 | 412       |
| 31 | Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .  | 0.2  | 62        |
| 32 | Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7852-7857.  | 3.3  | 479       |
| 33 | Recognition of influenza H3N2 variant virus by human neutralizing antibodies. <i>JCI Insight</i> , 2016, 1, .  | 2.3  | 20        |
| 34 | DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0125914.   | 1.1  | 17        |
| 35 | Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old. <i>Journal of Infectious Diseases</i> , 2015, 212, 552-561.   | 1.9  | 11        |
| 36 | Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3050-3055.   | 3.3  | 111       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i> , 2015, 33, 5225-5234.                                     | 1.7 | 92        |
| 38 | Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009–2010 seasonal trivalent influenza vaccinations. <i>Vaccine</i> , 2015, 33, 163-173.   | 1.7 | 3         |
| 39 | LB-2Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response. <i>Open Forum Infectious Diseases</i> , 2014, 1, S66-S67.  | 0.4 | 0         |
| 40 | Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1409.  | 3.8 | 126       |
| 41 | A Randomized, Double-Blind, Controlled Trial of the 17D Yellow Fever Virus Vaccine Given in Combination with Immune Globulin or Placebo: Comparative Viremia and Immunogenicity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 172-177. | 0.6 | 27        |
| 42 | Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine. <i>Tropical Medicine &amp; Surgery</i> , 2013, 1, 117.                            | 0.1 | 2         |
| 43 | <i>Fusarium falciforme</i> Vertebral Abscess and Osteomyelitis: Case Report and Molecular Classification. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2350-2353.   | 1.8 | 21        |
| 44 | Cytotoxic T-Lymphocyte Responses to Canarypox Vector-Based HIV Vaccines in HIV-Seronegative Individuals: A Meta-analysis of Published Studies. <i>HIV Clinical Trials</i> , 2004, 5, 259-268.  | 2.0 | 12        |